Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Equity (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Return on Equity data on record, last reported at 0.62% in Q4 2025.

  • For Q4 2025, Return on Equity rose 32.0% year-over-year to 0.62%; the TTM value through Dec 2025 reached 0.62%, up 32.0%, while the annual FY2025 figure was 0.53%, 31.0% up from the prior year.
  • Return on Equity reached 0.62% in Q4 2025 per ACRS's latest filing, up from 1.15% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.27% in Q2 2021 and bottomed at 1.15% in Q3 2025.
  • Average Return on Equity over 5 years is 0.57%, with a median of 0.49% recorded in 2024.
  • Peak YoY movement for Return on Equity: skyrocketed 41bps in 2024, then plummeted -85bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.43% in 2021, then grew by 1bps to 0.43% in 2022, then tumbled by -41bps to 0.61% in 2023, then tumbled by -55bps to 0.94% in 2024, then surged by 34bps to 0.62% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.62% in Q4 2025, 1.15% in Q3 2025, and 1.0% in Q2 2025.